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Abstract
Branching morphogenesis of the murine mammary gland starts during late embryogenesis. It is regulated by the signals ema-
nating both from the epithelium and the mesenchyme, yet the molecular mechanisms regulating this process remain poorly
understood. We have previously developed a unique whole organ culture technique for embryonic mammary glands, which
provides a powerful tool to monitor and manipulate branching morphogenesis ex vivo. Nowadays, RNA sequencing and other
transcriptional profiling techniques provide robust methods to identify components of gene regulatory networks driving
branching morphogenesis. However, validation of the candidate genes still mainly depends on the use of the transgenic mouse
models, especially in mammary gland studies. By comparing different serotypes of recombinant adeno-associated virus
(rAAVs), we found out that rAAVs provide sufficient efficiency for gene transfer with different tissue preferences depending
on the serotypes of the virus. AAV-2 and AAV-8 preferentially target epithelial and mesenchymal compartments, respectively,
while AAV-9 infects both tissues. Here, we describe a protocol for AAV-mediated gene transfer in ex vivo cultured murine
embryonic mammary gland facilitating gene function studies on mammary gland branching morphogenesis.
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Introduction
The embryonic development of the mammary gland in mouse
starts at embryonic day (E) 10 with the formation of milk
lines, which are two discontinued stripes of ventral lateral
surface ectoderm between the fore and hind limb [1–3]. One
day later, 5 pairs of symmetrically positioned mammary rudi-
ments named placodes have formed, presumably by cell mi-
gration [4, 5]. By E13, placodes have extended into the un-
derlying mesenchyme to form buds and are now surrounded
by a condensed, mammary-specific mesenchyme [6, 7].
Starting from E15-E16, depending on the strain of mouse,
the mammary bud starts sprouting and invades into the under-
lying fat pad, the precursor of adult mammary gland stroma.
By E18.5 (just before birth), the mammary gland forms a
small ductal tree with about 10–15 branches. After birth,
mammary gland development is slow until the onset of the
puberty. The interaction between mesenchymal and epithelial
cells is essential for mammary gland morphogenesis at all
developmental stages.
Due to the technical difficulties in studying the mammary
branching morphogenesis and epithelial-mesenchymal inter-
actions in vivo, several ex vivo culture methods have been
developed. For example, epithelial organoids are cultured in
various 3-dimensional (3D) matrices, but typically these cul-
tures lack stromal cells, and hence the crucial epithelial-
stromal crosstalk known to be essential for normal develop-
ment [8, 9]. Organ culture is a powerful method widely used
in developmental biology studies. We have previously
established a whole organ culture technique as an alternative
for organoid cultures, where embryonic mammary buds are
microdissected with the surrounding stroma and cultured
ex vivo [10, 11]. This method was initially developed in the
60’s [12], but it has not been used much by the scientific
community ever since, likely due to technical challenges.
We have developed this technique further, and now we
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routinely culture embryonic mammary glands from E12.5 to
E13.5 for 3–7, even up to 9 days. During this time, the ductal
system forms, it invades the stroma and branches essentially
as in vivo. This system allows us to monitor and to manipulate
(e.g. growth factors or drugs can be added and washed away)
ductal invasion ex vivo.
Genetically modified mice remain one of the most
widely used tools for analyzing gene function in mam-
malian development. However, the generation of genet-
ically modified mice is costly and time-consuming,
which severely limits their applications, especially in
the post-genome era. Thus, gene modification in
ex vivo cultured organs would be an ideal technique
for gene function analysis before in vivo analysis of
transgenic animals, especially when growth factors or
drugs are not available. Although siRNA transfection
has been successfully applied in ex vivo cultured em-
bryonic kidneys [13] and salivary glands [14] already
nearly two decades ago, their use has not been wide-
spread. Furthermore, at least in our hands, epithelial
cells of the embryonic mammary glands are refractory
to transfection reagents such as Lipofectamine 3000
(Invitrogen), Lipofectamine RNAiMAX (Invitrogen)
and HiPerFect (QIAGEN) in whole organ cultures (un-
published observations). Hsu et al. have compared dif-
ferent virus-mediated gene transfer methods in ex vivo
cultured salivary glands and observed virus-type depen-
dent selective targeting to epithelial or mesenchymal
cells [15]. This pioneering study encouraged us to look
for a feasible gene transfer method in the ex vivo cul-
tured embryonic mammary gland. Here, we describe a
protocol for recombinant adeno-associated virus
(rAAVs)-mediated gene transfer method in ex vivo cul-
tured murine embryonic mammary gland facilitating
gene function studies during mammary gland branching
morphogenesis.
Reagents, Solutions and Materials
1. Sterile Dulbecco’s phosphate-buffered saline (DPBS,
D5652, Sigma-Aldrich)
2. Sterile Phosphate-buffered saline (PBS; P4417, Sigma-
Aldrich)
3. F-12/DMEM culture medium: Prepare the medium by
mixing F-12-GlutaMAX (31765, Thermo Fisher) with
DMEM-GlutaMAX (651965, ThermoFisher) at a 1:1 ra-
tio and supplement with 10% (vol/vol) heat-inactivated
fetal bovine serum (FBS; SV30160.03, HyClone/
Thermo Fisher) and 20 U/ml penicillin-streptomycin
(PS; 15140, Gibco/ Thermo Fisher)
4. Ascorbic acid (A4544, Sigma-Aldrich). 100 mg/ml stock so-
lution is prepared by reconstitution in water and then filter-
sterilized with a 0.22 μm filter (SCGPCARE, Millipore/
Merck). The solution is divided into single-use aliquots and
store at−20 °C andprotected from light.Dilute 1:1000 inF12/
DMEM culture medium right before use.
5. Dispase II (4942078001, Roche). Dissolve the powder to
a final concentration of 1.25 U/ml in PBS and filter-
sterilize with a 0.22 μm filter. Always use a freshly made
working solution.
6. Thyrode’s solution (pH 7.4). Dissolve the following
chemicals into 900 ml of MilliQ water:
& 8.0 g NaCl (S5886, Sigma-Aldrich)
& 0.2 g KCl (P5405, Sigma-Aldrich)
& 0.05 g NaH2PO4 + H2O (S3522, Sigma-Aldrich)
& 1.0 g D-(+)-Glucose (G7021, Sigma-Aldrich)
& 1.0 g NaHCO3 (S5761, Sigma-Aldrich)
Adjust the pH to 7.4 and addMilliQ water to a final volume
of 1000 ml. The solution is filter-sterilized with a 0.22 μm
filter and stored at 4 °C for use.
7. 10x Pancreatin stock solution. Dissolve 0.85 g NaCl
(S5886, Sigma-Aldrich) and 2.5 g Pancreatin (P3292,
Sigma-Aldrich) into 100 ml of MilliQ water on a mag-
netic stirrer on ice for 3–4 h (or at 4 °C o/n). Remove the
insoluble impurities by centrifugation at 5000 rpm for
10min and filter-sterilize the supernatant with a 0.22μm
filter (usually at least two 0.22 μm filters will be needed
to pass a volume of 100 ml due to the viscosity). Divide
the solution into 1 ml aliquots (The stock solution can be
used at least for 1 year when stored at −20 °C).
8. Pancreatin-trypsin working solution (pH 7.4). Dissolve
0.225 g of trypsin (T4799, Sigma-Aldrich/Merck) into
6-ml of Thyrode’s solution using a magnetic stirrer on
ice. Add 1 ml of 10X pancreatin stock solution and 20 μl
of PS (10,000 U/ml in stock) and adjust pH to 7.4 with
NaOH. Adjust the volume to 10 ml with Thyrode’s so-
lution and filter-sterilize with a 0.22μm filter. Divide the
solution into 1 ml aliquots and store at −20 °C. The
working solution is stable for 2–3 weeks at −20 °C. Do
not re-freeze the solution after thawing.
9. Nuclepore polycarbonate filters (pore size: 1 μm.
110610, Whatman). Sterilize and store the filters in
70% ethanol at room temperature. Wash the filter with
sterilized PBS inside laminar hood three times and cut
the filter to approximately 5 mm squares in PBS in ad-
vance. The filter squares can be stored in PBS at 4 °C for
1–2 weeks.
10. 35 mm plastic Petri dishes (121V, Sterilin/Thermo
Scientific)
11. Glass Pasteur pipettes
12. Horizontal laminar flow hood
13. Stereo microscope with camera
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14. Metal grids: Corrosion-resistant stainless-steel mesh
(0.7 mm mesh size) is cut into approximately 30 mm
diameter disks and the edges are bent to reach about
3 mm height. Make small holes (e.g. 2 rows of 3) into
the grid to facilitate the observation of the explants.
Grids can be washed and autoclaved multiple times.
Alternatively, commercial cell culture inserts could be
used to replace the grid and Nuclepore filters.
15. Two disposable 26-gauge (303800, BD Microlance) or
25-gauge (300600, BD Microlance) needles attached to
1 ml plunger-removed disposable plastic syringes
(303172, BD Plastipak).
16. Recombinant adeno-associated virus (rAAVs). Different
serotypes of rAAVs (AAV-2, AAV-8 and AAV-9) were
purchased from AAV Gene Transfer and Cell Therapy
Core Facility, Faculty of Medicine, University of
Helsinki. The virus particles were produced with viral
vector pSub-CAG-WPRE-Cre and corresponding pack-
aging vectors.
17. Virkon (LANXESS). Dissolve the powder in water. 1%
(m/v) for surface disinfection. In order to disinfect the
liquid waste, mix with 5% (m/v) Virkon with 1:1 ratio in
a sealed container and incubate in room temperature for
15 min.
18. (Optional) tdTomato reporter mouse (007914, The
Jackson Laboratory). In order to better illustrate the virus
infection efficiency, we used tdTomato Cre reporter
mouse [16] in this protocol. When crossed with a
wildtype mouse, all the offspring carry one allele of
tdTomato reporter gene, which contains a floxed stop
cassette before the coding region and prevents the ex-
pression of the gene. After rAAV-Cre infection, the Cre
recombinase translated from the viral genome will in-
duce DNA recombination to remove the stop cassette in
the virus-infected cells and initiate the expression of
tdTomato (Fig. 1a).
19. (Optional) 4% PFA (Parafomaldehyde) in PBS (multiple
suppliers).
20. (Optional) 0.3% PBST. 0.3% (vol/vol) Triton X-100
(04807423, MP Biomedicals) in PBS.
21. (Optional) Blocking solution. 5% (vol/vol) goat serum
(16210064, Gibco/Thermo Fisher), 0.5% (mass/vol)
BSA (A2153, Sigma-Aldrich) in 0.3% PBST.
22. (Optional) Confocal microscope. Zeiss LSM700 or
Leica SP8 with suitable laser source.
23. (Optional) Rat Anti-Mouse CD326 (EpCAM) antibody
(552370, BD Pharmingen, 1:2000).
24. (Optional) Goat anti-Rat IgG, Alexa Fluor 647
(A-21247, Invitrogen/ThermoFisher Scientific, 1:1000).
25. (Optional) Hoechst 33342 (H3570, Invitrogen/
ThermoFisher Scientific, 1:1000)




1. (Day 0) The mammary tissue is dissected as previously de-
scribed [11]. Briefly, E13-E13.5mouse embryos are removed
from the uterus and dissected in DPBS. The flank skin of the
mammary region is carefully dissected outwith small scissors.
All the explants are transferred to a 35 mm plastic Petri dish
using a Pasteur pipette and proceed to step 2.
Separation of the Skin Epithelium from the
Mesenchyme
The separation procedure is modified from the protocol pre-
viously described [11] to facilitate the process.
2. Replace DPBS with 2 ml freshly prepared 1.25 U/ml
Dispase II solution in a 35 mm plastic Petri dish.
3. Keep the Petri dish on a linear shaker mixer with speed
around 40 rpm in 4 °C for 15–25 min, depending on the
age of the embryos (longer treatment time for older em-
bryos) and the activity of the enzymes. Check the explants
under the stereomicroscope and proceed to step 4 when
epithelium and mesenchyme appear separated at the edge
of the explants (Note 1).
4. Replace the Dispase II solution with pancreatin-trypsin
working solution and incubate for 4–5 min at room tem-
perature. To aid the process, gently manually rotate the
Petri dish horizontally. Monitor the tissues under the ste-
reomicroscope to determine the optimal incubation time.
Proceed to step 5 when a big piece of epithelium starts to
release from the explants.
5. Replace the pancreatin-trypsin working solution with
F-12/DMEM culture medium to inactivate the enzyme
activity. Recover the tissue on ice for 30–45 min and
protect from light if necessary.
6. After incubation, transfer the explants to a small glass
Petri dish using a glass Pasteur pipette. Add enough fresh
F-12/DMEM culture medium to cover all the explants and
remove the skin epithelium by using needles with 1 ml
plunge-removed syringes under the stereomicroscope.
7. Proceed to step 8a for virus infection of whole explants
(option 1) or step 8b for virus infection of mammary buds
in a hanging drop (option 2).
Virus Infection of the Whole Explant (Option 1)
Virus infection can be performed directly on the whole cul-
tured explants. The tissue culture is performed as previously
described [11] with minor modifications.
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8a. Place a sterilized metal grid on a 35 mm plastic
Petri dish.
9a. Prepare the culture medium by adding ascorbic acid
stock solution into F-12/DMEM culture medium to a
final concentration of 100 μg/ml. Only use culture me-
dium with a fresh supplement of ascorbic acid.
10a. Add the culture medium on top of the metal grid and
avoid trapping any air bubbles underneath the grid.
11a. Transfer the explants with filter squares to the top of the
metal grid. To get optimal rAAVs infection efficiency,
use filters with pore size of 1.0 μm instead of 0.1 μm in
the original protocol [11] (Fig. 1c-d) (Note 2).
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12a. Culture tissues in a humidified incubator at 37 °C with
an atmosphere of 5% CO2 and perform rAAVs infec-
tion the next day.
13a. (Day 1) Change 2 ml of F-12/DMEM culture medium
freshly supplemented with ascorbic acid.
14a. Add rAAVs into the medium to optimal virus concen-
tration (Note 3 and 8). From this step, all the dispos-
ables and waste solutions should be collected cautious-
ly (Note 4). Depending on the purpose of the experi-
mental design, different serotypes of rAAVs can be
used. Although there are no exclusive differences, we
found that AAV-2 and AAV-8 preferentially target ep-
ithelial and mesenchymal compartments, respectively,
while AAV-9 infects both tissues (Fig. 1e-f) (Note 6).
15a. (Day 3) Two days later, change 2 ml/dish of fresh virus
free F-12/DMEM culture medium freshly supplemented
with ascorbic acid. Continue changing the medium every
second day until sufficient branching events are observed.
16a. Proceed to step 20 for fixation and visualization.
Virus Infection of Mammary Buds in a Hanging Drop
(Option 2)
In order to further increase the specificity of the infec-
tion in epithelial cells, an alternative method of virus
infection is performed in isolated mammary buds
(MBs) in a hanging drop (Fig. 2).
8b. (Day 0) Further dissect the MBs out from the mesen-
chyme with needles. Try to keep the mesenchyme as
intact as possible (Online Resource 1: Fig. S1a-b).
9b. Collect the mesenchyme and perform normal culture as
described in step 8a-12a.
10b. Remove the surrounding mesenchyme from the
MBs as much as possible. Be cautious not to
punch the MBs with the needle and discard the
damaged MBs, as the MBs are very sensitive and
will not grow if damaged.
11b. Collect the MBs to a new 35 mm plastic Petri dish
using a small pipette with a 10 μl plastic pipette tip.
Pre-coat the pipette tip with culture medium before use
to avoid the MBs adhering to the surface of pipette tip.
12b. Gently pipette the MBs with fresh culture medium sev-
eral times to further dissociate the MBs from the sur-
rounding mesenchyme (Fig. 2a).
13b. Dilute the rAAVs to an optimal concentration with cul-
ture medium (Note 3 and 8). Starting from this step, all
the disposables and waste solutions should be collected
cautiously (Note 4).
14b. Collect theMBs to the cap of a new 35mm plastic Petri
dish in a drop (Fig. 2a). Replace the medium with 10–
20μl virus-containingmedium and flip the cap to cover
the Petri dish containing sterilized H2O to avoid drying
of the drop. Incubate the Petri dish in the humidified
incubator at 37 °C with an atmosphere of 5% CO2 for
2.5 h for infection (Note 5).
15b. Wash the MBs gently with fresh culture medium for 2–
3 times by replacing the liquid.
16b. Use a small pipette with pre-coated 10 μl plastic pipette
tip to transplant the MBs one by one to the top of the
cultured mesenchyme from step 9b under the stereomi-
croscope. (Note 7, Online Resource 1: Fig. S1c-i)
i. Adjust the volume setting for the pipette to 10 μl and
pre-coat the plastic tip by aspirating 2–3 times F-12/
DMEM culture medium.
ii. Push the plunger in the air at the stop and place the tip
into the fresh F-12/DMEM culture medium.
iii. Release the plunger halfway to aspirate approximately
4–5 μl medium and then place the tip to the medium
with virus infectedMBs (Online Resource 1: Fig. S1c).
iv. Release the plunger gently to aspirate one MB and
pause immediately when the MB entered the tip
(Online Resource 1: Fig. S1d-e).
v. Hold the position of the plunger. If the pre-
coating works well, the MB should not stick to
the inner surface of the tip and you can see the
MB entering the tip under the stereomicroscope.
Move the tip out of the medium before the MB
drops out from the tip and try to keep the MB
at the opening of the tip.
Fig. 1 Virus infection on the whole explant. a. Schematic diagram
illustrating the model used in this protocol. b. Scheme illustrating the
schedule of the experiment. c-d. The filter with 1.0 μm pore size shows
higher rAAVs infection efficiency compared with 0.1 μm. The explants
were incubated in culture medium containing 1.4 × 109 vg (virus
genome)/ml AAV2-Cre (which harbors Cre recombinase) for 2 days.
All the progenies of the infected cells will be labelled with tdTomato
expression. The images were taken with stereomicroscope on day 2, 4
and 6 to monitor the growth of mammary buds and the expression of
tdTomato reporter genes (c). The exposure time of tdTomato expression
has been labelled in the image. The virus infection efficiency has been
further confirmed by whole mount fluorescent immunostaining with anti-
EpCAM antibody and Hoechst 33342 to visualize the epithelial cells and
nuclei, respectively, and imaged with Zeiss LSM700 confocal micro-
scope and the representative images of optical section were shown (d).
e-f. Different serotype of rAAVs preferentially target different tissues.
The explants were incubated in culture medium containing 8.6 × 109
vg/ml AAV2-Cre, AAV8-Cre or AAV9-Cre, respectively, for 2 days.
7 days after culture, the virus infection efficiency was further confirmed
by whole mount fluorescent immunostaining and confocal microscope
and the representative images of optical section were shown (e). The
infection efficiency in mammary epithelium and mesenchyme compart-
ment from the same explant was determined separately by quantifying the
progenies of infected and non-infected cells using Imaris 9.2 software
(Bitplane). The figure was produced with R, a free software environment
available at http://www.r-project.org/, and ggplot2 package [18] (f). The
data are presented as mean ± SD. Statistical comparisons were performed
by paired Student’s t test
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vi. Push the plunger a bit in the air to force the liquid
surface out of the plastic tip without forming any
drop. In this case, the MB will move closer to the
opening of the tip.
vii. Touch the mesenchyme with the tip gently
without pushing the plunger and the MB will
be stuck with the mesenchyme (Online
Resource 1: Fig. S1f-i).
viii. Repeat the above steps to transplant the MB one by
one.
17b. Incubate the MBs with mesenchyme in the humidified
incubator at 37 °C with an atmosphere of 5% CO2.
18b. (Day 2) Change 2 ml/dish of fresh virus-free F-12/
DMEM culture medium freshly supplemented with
ascorbic acid. Continue changing the medium every
second day until sufficient branching events are ob-
served (Fig. 2b).
19b. Proceed to step 20 for fixation and visualization.
Fixation and Visualization
The explants can be fixed and processed for carmine alum
staining, conventional histology or whole-mount immunoflu-
orescence staining for confocal microscopy [11, 16, 17].
20. (Optional) Whole-mount immunofluorescence staining.
i. Fix the samples in 4% PFA at 4 °C overnight with
gentle shaking.
ii. Wash the samples three times 20–30 min with PBS at
room temperature (RT) on a shaker.
iii. Permeabilize the samples with 0.3% PBST for two
hours at RT.














































Fig. 2 Virus infection of
mammary buds in a hanging
drop. a. Scheme illustrating the
procedure and schedule of the
experiment. b-c. Example of
growing mammary buds (MBs)
infected within 15 μl hanging
drop containing 1.45 × 1012 vg/ml
AAV8-Cre (stock in PBS).
Images were taken 7 days after
culture with stereomicroscope
before fixation (b) or Leica SP8
confocal microscope after whole
mount fluorescent immunostain-
ing with EpCAM antibody and
Hoechst 33342 and the represen-
tative images of optical section
were shown (c)
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v. Remove the blocking solution and incubate the sam-
ples with antibody diluent consisting of EpCAM an-
tibody (1:1000) and Hoechst 33342 (1:1000) in
blocking solution at 4 °C with gentle shaking for
1–2 days.
vi. Remove the antibody diluent and wash the sample
three times 20–30 min with 0.3% PBST at RT.
vii. Add secondary antibody dissolved in 0.3% PBST
solution containing 1% BSA (mass/vol) and incu-
bate at 4 °C overnight.
viii. Remove the antibody diluent and wash the sample
three times 20–30 min with 0.3% PBST at RT.
ix. Wash the samples three times 20–30 min with
PBS at RT.
x. Incubate the samples with 4%PFA for 10min at RT.
xi. Remove the PFA and wash the sample three times
20–30 min with PBS at RT.
xii. Store the samples in PBS at at 4 °C or mount slides
with Vectashield Mounting Medium and a glass
coverslip for imaging with confocal microscope.
Notes
1. The enzymatic activity varies, and the duration of
the treatment may be different depending on the
batches, especially for pancreatic-trypsin treatment.
Some of the mesenchyme may be lost during the
treatment, therefore monitor the pancreatic-trypsin
treatment frequently and inactivate the enzyme if
large pieces of mesenchyme start detaching from
the rest of the explant or the solution becomes very
viscous. The separation will be more obvious during
the recovery time in step 5.
2. The transparency of the filter paper with the pore
size of 1.0 μm is lower than that of the 0.1 μm
pore sized filter. Although the mammary gland is
still visible, it is more difficult to monitor branching
morphogenesis using transmitted light when using
the 1.0 μm filter paper.
3. Depending on the supplier and serotype, the rAAVs
can be delivered within different solutions, typically
in PBS or iodixanol solution. In our test, high con-
centration of iodixanol solution inhibits the out-
growth of the cultured mammary gland, and a min-
imal 1:20 dilution of virus stock is needed to min-
imize the toxicity to an acceptable level.
4. Be cautious about the biosafety containment rules.
Usually, the production of rAAVs must be handled
at Biosafety Level 2 (BSL-2), but infection of
rAAVs could be handled at BSL-1. However, if
any hazardous transgene is included, BSL-2 contain-
ment rules apply. For disinfection, we use 1%
Virkon solution for the surface and 1:1 mixture with
5% Virkon solution for waste liquid with 15–30 min
incubation at room temperature.
5. Mesenchyme is crucial for keeping the identity of
the mammary epithelium. In our test, mammary
buds do not grow in mammary mesenchyme if they
are incubated first in a hanging drop for a prolonged
period of 3–4 h. Iodixanol solution coming with
rAAVs stock decreases the time window further.
To avoid this, try to use rAAVs with a high titer
or delivered in PBS.
6. Several factors influence the expression level of a
transgene carried by the virus genome, including
the virus infection efficiency (which also influences
the copy number of the virus genome in the cell)
and the promoter used to drive transgene expression.
Depending on the purpose of the experiment, selec-
tion of the right serotype of the rAAVs will signif-
icantly increase infection efficiency. However, for
an optimal expression of a transgene in a specific
tissue, the efficiency of different promoters should
be further evaluated. For example, a transgene driv-
en by keratinocyte-specific promoter, delivered in
AAV2, is likely to specifically and efficiently ex-
press in mammary epithelial cells even using the
whole explant infection method (option 1).
7. In order to avoid interaction of MBs close to each other,
we normally transplant only one or two MBs to each
cultured mesenchyme. If there are two, try to keep them
far away from each other.
8. According to our experience, by using the whole
explant infection method (option 1), 3.2 × 109 to
8.6 × 109 vg/ml AAV2-Cre or 8.6 × 109 to 9.7 ×
1010 vg/ml AAV9-Cre are able to infect around
20–50% epithelial cells. Meanwhile, 8.6 × 109 vg/
ml AAV8-Cre is able to infect around 50–60% mes-
enchymal cells. On the other hand, by using the
hanging drop infection method (option 2), 1.45 ×
1012 vg/ml AAV8-Cre or 6.77 × 1011 vg/ml AAV9-
Cre are able to infect around 50–60% epithelial
cells, which is much higher in concentration but less
in total amount of virus that has been used in op-
tion 1. Due to the low titer of the AAV2-Cre virus
available to us and toxicity of iodixanol solution,
we were unable to apply AAV2-Cre to MBs (option
2) with sufficient efficiency without significantly
compromising the outgrowth of the mammary gland.
Based on our experience, we would suggest 5 × 1010
vg/ml AAV2-Cre as a starting point for the trial to
target around 50% epithelial cells.
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